

Giovanna Liuzzo,, Fesc

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5130943/publications.pdf>

Version: 2024-02-01

182
papers

11,667
citations

53794

45
h-index

27406

106
g-index

195
all docs

195
docs citations

195
times ranked

9394
citing authors

#	ARTICLE	IF	CITATIONS
1	Computed tomography coronary angiography in acute chest pain: an excellent diagnostic tool with poor added value on clinical outcomes. <i>European Heart Journal</i> , 2022, 43, 103-104.	2.2	0
2	Air Pollution and Coronary Plaque Vulnerability and Instability. <i>JACC: Cardiovascular Imaging</i> , 2022, 15, 325-342.	5.3	30
3	VANISHing the progression of cardiac abnormalities in hypertrophic cardiomyopathy with early use of valsartan?. <i>European Heart Journal</i> , 2022, 43, 181-182.	2.2	1
4	Therapeutic-dose heparin should integrate the standard of care of moderately ill patients with COVID-19 admitted to hospital. <i>European Heart Journal</i> , 2022, 43, 365-366.	2.2	0
5	Volume of physical activity and cardiovascular health status: is more necessarily better?. <i>European Heart Journal</i> , 2022, 43, 1286-1287.	2.2	2
6	Myocarditis after BNT162b2 mRNA SARS-CoV-2 vaccine: low incidence and mild severity. <i>European Heart Journal</i> , 2022, , .	2.2	3
7	Can low-dose aspirin help the RECOVERY of patients hospitalized with COVID-19?. <i>European Heart Journal</i> , 2022, 43, 714-715.	2.2	0
8	Can targeting factor XIa dissociate thrombosis from haemostasis?. <i>European Heart Journal</i> , 2022, , .	2.2	1
9	Give genotype-guided dual antiplatelet therapy a second CHANCE. <i>European Heart Journal</i> , 2022, , .	2.2	1
10	OUP accepted manuscript. <i>European Heart Journal</i> , 2022, , .	2.2	0
11	OUP accepted manuscript. <i>European Heart Journal</i> , 2022, , .	2.2	2
12	Molecular Hallmarks of Ischemia with Non-Obstructive Coronary Arteries: The "INOCA versus Obstructive CCS" Challenge. <i>Journal of Clinical Medicine</i> , 2022, 11, 1711.	2.4	5
13	Advances and Challenges in Biomarkers Use for Coronary Microvascular Dysfunction: From Bench to Clinical Practice. <i>Journal of Clinical Medicine</i> , 2022, 11, 2055.	2.4	9
14	SARS-CoV-2 infection markedly increases long-term cardiovascular risk. <i>European Heart Journal</i> , 2022, 43, 1899-1900.	2.2	6
15	PARADISE-MI suggests a limited role of intensified neuro-hormonal inhibition in the management of acute myocardial infarction with reduced ejection fraction. <i>European Heart Journal</i> , 2022, 43, 559-560.	2.2	4
16	Attilio Maseri: scientist, clinician, mentor, and gentleman. <i>Cardiovascular Research</i> , 2022, 118, e57-e58.	3.8	1
17	A novel inhibitor of Factor XIa as potential haemostasis-sparing anticoagulant for patients with atrial fibrillation. <i>European Heart Journal</i> , 2022, 43, 2354-2355.	2.2	1
18	The absolute cardiovascular benefits of PCSK9 inhibitors and ezetimibe added to maximally tolerated statin therapy depend on individual baseline cardiovascular risk. <i>European Heart Journal</i> , 2022, 43, 3016-3017.	2.2	3

#	ARTICLE	IF	CITATIONS
19	Brain-derived neurotrophic factor in patients with acute coronary syndrome. <i>Translational Research</i> , 2021, 231, 39-54.	5.0	6
20	Platelet hyaluronidase 2 enrichment in acute coronary syndromes: a conceivable role in monocyte-platelet aggregate formation. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2021, 36, 785-789.	5.2	8
21	OUP accepted manuscript. <i>European Heart Journal</i> , 2021, 42, 4789-4790.	2.2	3
22	Marked von Willebrand factor and factor VIII elevations in severe acute respiratory syndrome coronavirus-2-positive, but not severe acute respiratory syndrome coronavirus-2-negative, pneumonia: a caseâ€“control study. <i>Blood Coagulation and Fibrinolysis</i> , 2021, 32, 285-289.	1.0	16
23	A one-size-fits-all polypill strategy for primary prevention in the era of precision medicine?. <i>European Heart Journal</i> , 2021, 42, 561-562.	2.2	2
24	Re-purposed antiviral drugs without a purpose in COVID-19: a valuable lesson for clinicians. <i>European Heart Journal</i> , 2021, 42, 882-883.	2.2	2
25	When less is more: dual antiplatelet therapy in elective percutaneous coronary intervention. <i>European Heart Journal</i> , 2021, 42, 965-966.	2.2	2
26	Colchicine in ischemic heart disease: the good, the bad and the ugly. <i>Clinical Research in Cardiology</i> , 2021, 110, 1531-1542.	3.3	22
27	GLP-1 receptor agonists: fighting obesity with an eye to cardiovascular risk. <i>European Heart Journal</i> , 2021, 42, 1652-1653.	2.2	5
28	Interleukin-1 blockade: a paradigm shift in the treatment of patients with recurrent pericarditis?. <i>European Heart Journal</i> , 2021, 42, 1287-1288.	2.2	0
29	Personalized Clinical Phenotyping through Systems Medicine and Artificial Intelligence. <i>Journal of Personalized Medicine</i> , 2021, 11, 265.	2.5	14
30	StatinWISE sheds new light on statin-related muscle symptoms. <i>European Heart Journal</i> , 2021, 42, 1726-1727.	2.2	2
31	Modulating the gut microbiome with dietary interventions to reduce cardiometabolic disease risk. <i>European Heart Journal</i> , 2021, 42, 2152-2153.	2.2	3
32	Upregulated monocyte expression of PLIN2 is associated with early arterial injury in children with overweight/obesity. <i>Atherosclerosis</i> , 2021, 327, 68-75.	0.8	7
33	Are US cardiologists ADAPTABLE to considering low-dose aspirin for secondary prevention?. <i>European Heart Journal</i> , 2021, 42, 2525-2526.	2.2	1
34	Glucagon-Like Peptide-1 (GLP-1) Receptor Agonism and Exercise: An Effective Strategy to Maintain Diet-Induced Weight Loss. <i>European Heart Journal</i> , 2021, 42, 2628-2629.	2.2	0
35	Unhealthy lifestyles mediate only a small proportion of the socioeconomic inequalitiesâ€™ impact on cardiovascular outcomes in US and UK adults: a call for action for social cardiology. <i>European Heart Journal</i> , 2021, 42, 2420-2421.	2.2	2
36	Occluding to prevent occlusion. <i>European Heart Journal</i> , 2021, 42, 3224-3225.	2.2	0

#	ARTICLE	IF	CITATIONS
37	Aspirin-free antiplatelet strategies: is the evidence supporting a paradigm shift?. European Heart Journal, 2021, 42, 4011-4012.	2.2	2
38	No blossom for fractional flow reserve in FLOWER-MI. European Heart Journal, 2021, 42, 2971-2972.	2.2	1
39	Does abbreviated dual antiplatelet therapy after PCI provide a clinically meaningful trade-off between bleeding and ischaemic events in patients at high risk for bleeding?. European Heart Journal, 2021, 42, 4418-4419.	2.2	1
40	An inflammatory ageing clock to detect cardiovascular and other age-related diseases: a new approach to preventive medicine. European Heart Journal, 2021, 42, 4296-4297.	2.2	1
41	First in man: gene editing for the treatment of transthyretin amyloidosis. European Heart Journal, 2021, 42, 3597-3598.	2.2	0
42	Role of perilipin 2 in microvascular obstruction in patients with ST-elevation myocardial infarction. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 633-642.	1.0	3
43	A case report of coronary artery spasm and takotsubo syndrome: exploring the hidden side of the moon. European Heart Journal - Case Reports, 2021, 5, ytaa477.	0.6	5
44	COVID 19: in the eye of the cytokine storm. European Heart Journal, 2021, 42, 150-151.	2.2	15
45	A fixed-dose combination treatment strategy to reduce premature cardiovascular disease deaths globally. European Heart Journal, 2021, 43, 16-17.	2.2	0
46	A Novel Monocyte Subset as a Unique Signature of Atherosclerotic Plaque Rupture. Frontiers in Cell and Developmental Biology, 2021, 9, 753223.	3.7	7
47	Monocyte-Platelet Aggregates Triggered by CD31 Molecule in Non-ST Elevation Myocardial Infarction: Clinical Implications in Plaque Rupture. Frontiers in Cardiovascular Medicine, 2021, 8, 741221.	2.4	2
48	Clinical, angiographic and echocardiographic correlates of epicardial and microvascular spasm in patients with myocardial ischaemia and non-obstructive coronary arteries. Clinical Research in Cardiology, 2020, 109, 435-443.	3.3	35
49	Promises and challenges of targeting inflammation to treat cardiovascular disease: the post-CANTOS era. European Heart Journal, 2020, 41, 2164-2167.	2.2	18
50	Low-Dose Edoxaban for Stroke Prevention in Elderly Patients with Atrial Fibrillation: Comment on the Edoxaban Low-Dose for Elder Care Atrial Fibrillation Patients (ELDERCARE-AF) Trial. European Heart Journal, 2020, 41, 3882-3883.	2.2	3
51	CD8 lymphocytes and plaque erosion: a new piece in the jigsaw. European Heart Journal, 2020, 41, 3561-3563.	2.2	8
52	Low-dose colchicine: a new tool in the treatment of chronic coronary disease? <i>Comment on the low-dose colchicine (LoDoCo)2 trial</i>. European Heart Journal, 2020, 41, 3880-3881.	2.2	4
53	EMPEROR-Reduced supports the use of SGLT2 inhibitors for the treatment of patients with heart failure and reduced ejection fraction: <i>Comment on the EMPEROR-Reduced trial</i>. European Heart Journal, 2020, 41, 3881-3882.	2.2	0
54	The widely promoted antimalarial drug hydroxychloroquine confers no mortality benefit in hospitalized patients with COVID-19: <i>comment on the "Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19"</i>. European Heart Journal, 2020, 41, 4389-4390.	2.2	3

#	ARTICLE	IF	CITATIONS
55	Management of chronic kidney disease and its cardiovascular complications: has the dawn of a new era arrived? Comment on "Dapagliflozin in Patients with Chronic Kidney Disease". European Heart Journal, 2020, 41, 4231-4232.	2.2	1
56	Ubiquitous sex differences in tissue gene expression: the dawn of a new era for gender medicine. European Heart Journal, 2020, 41, 4090-4091.	2.2	1
57	Inflammation and Atherothrombosis. , 2019, , 935-946.e1.		4
58	Optical coherence tomography and C-reactive protein in risk stratification of acute coronary syndromes. International Journal of Cardiology, 2019, 286, 7-12.	1.7	13
59	EPIGENETIC EFFECT OF DIABETES ON CODING AND NON-CODING PLATELET TRANSCRIPTOME IN ACUTE CORONARY SYNDROME. Journal of the American College of Cardiology, 2019, 73, 55.	2.8	0
60	Coronary Atherosclerotic Phenotype and Plaque Healing in Patients With Recurrent Acute Coronary Syndromes Compared With Patients With Long-term Clinical Stability. JAMA Cardiology, 2019, 4, 321.	6.1	92
61	High-sensitivity cardiac troponin assays and acute coronary syndrome: a matter of sex?. Journal of Cardiovascular Medicine, 2019, 20, 504-509.	1.5	15
62	Correlation between CD4+CD28null T lymphocytes, regulatory T cells and plaque rupture: An Optical Coherence Tomography study in Acute Coronary Syndromes. International Journal of Cardiology, 2019, 276, 289-292.	1.7	25
63	Matrix metalloproteinase-9 might affect adaptive immunity in non-ST segment elevation acute coronary syndromes by increasing CD31 cleavage on CD4+ T-cells. European Heart Journal, 2018, 39, 1089-1097.	2.2	28
64	Addressing Acute Coronary Syndromes. Circulation, 2018, 137, 1100-1102.	1.6	17
65	Perilipin 2 levels are increased in patients with in-stent neoatherosclerosis: A clue to mechanisms of accelerated plaque formation after drug-eluting stent implantation. International Journal of Cardiology, 2018, 258, 55-58.	1.7	7
66	Alterations of Hyaluronan Metabolism in Acute Coronary Syndrome. Journal of the American College of Cardiology, 2018, 72, 1490-1503.	2.8	59
67	Indoleamine 2,3-Dioxygenase (IDO) Enzyme Links Innate Immunity and Altered T-Cell Differentiation in Non-ST Segment Elevation Acute Coronary Syndrome. International Journal of Molecular Sciences, 2018, 19, 63.	4.1	10
68	Inflammasome, T Lymphocytes and Innate-Adaptive Immunity Crosstalk: Role in Cardiovascular Disease and Therapeutic Perspectives. Thrombosis and Haemostasis, 2018, 118, 1352-1369.	3.4	18
69	Epicardial adipose tissue microbial colonization and inflammasome activation in acute coronary syndrome. International Journal of Cardiology, 2017, 236, 95-99.	1.7	34
70	MATRIX METALLOPROTEINASE 9 DRIVES THE SHEDDING OF CD31 IN ACUTE CORONARY SYNDROMES. Journal of the American College of Cardiology, 2017, 69, 94.	2.8	0
71	Not all plaque ruptures are born equal: an optical coherence tomography study. European Heart Journal Cardiovascular Imaging, 2017, 18, 1271-1277.	1.2	45
72	Where Does Inflammation Fit?. Current Cardiology Reports, 2017, 19, 84.	2.9	32

#	ARTICLE	IF	CITATIONS
73	Atorvastatin inhibits the immediate-early response gene EGR1 and improves the functional profile of CD4+T-lymphocytes in acute coronary syndromes. <i>Oncotarget</i> , 2017, 8, 17529-17550.	1.8	8
74	Adaptive Immunity Dysregulation in Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2107-2117.	2.8	48
75	Anti-inflammatory treatment of acute coronary syndromes: the need for precision medicine. <i>European Heart Journal</i> , 2016, 37, 2414-2416.	2.2	24
76	Effect of Remote Ischemic Preconditioning on Platelet Activation Induced by Coronary Procedures. <i>American Journal of Cardiology</i> , 2016, 117, 359-365.	1.6	31
77	N-Acetylcysteine and High-Dose Atorvastatin Reduce Oxidative Stress in an Ischemia-Reperfusion Model in the Rat Kidney. <i>Transplantation Proceedings</i> , 2015, 47, 2757-2762.	0.6	23
78	Between Death and Hope After Out-of-Hospital Cardiac Arrest. <i>Journal of the American College of Cardiology</i> , 2015, 65, 2115-2117.	2.8	1
79	Increased PTPN22 Expression and Defective CREB Activation Impair Regulatory T-Cell Differentiation in Non-ST-Segment Elevation Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1175-1186.	2.8	34
80	Reduced CD31 expression on CD14+CD16+ monocyte subset in acute coronary syndromes. <i>International Journal of Cardiology</i> , 2015, 197, 101-104.	1.7	6
81	Response to Letter Regarding Article, "Allergic Inflammation Is Associated With Coronary Instability and a Worse Clinical Outcome After Acute Myocardial Infarction". <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, .	3.9	0
82	Allergic Inflammation Is Associated With Coronary Instability and a Worse Clinical Outcome After Acute Myocardial Infarction. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, e002554.	3.9	23
83	Altered CD31 expression and activity in helper T cells of acute coronary syndrome patients. <i>Basic Research in Cardiology</i> , 2014, 109, 448.	5.9	28
84	Advances in mechanisms, imaging and management of the unstable plaque. <i>Atherosclerosis</i> , 2014, 233, 467-477.	0.8	41
85	Parvovirus B19 at the culprit coronary stenosis predicts outcome after stenting. <i>European Journal of Clinical Investigation</i> , 2014, 44, 209-218.	3.4	4
86	Predictors of Postoperative Atrial Fibrillation in Patients With Coronary Artery Disease Undergoing Cardiopulmonary Bypass: A Possible Role for Myocardial Ischemia and Atrial Inflammation. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2014, 28, 512-519.	1.3	28
87	Endothelial Progenitor Cells in Morbid Obesity. <i>Circulation Journal</i> , 2014, 78, 977-985.	1.6	23
88	Infections, immunity and atherosclerosis: Pathogenic mechanisms and unsolved questions. <i>International Journal of Cardiology</i> , 2013, 166, 572-583.	1.7	37
89	Effects of Drospirenone/Ethinylestradiol and/or Metformin on CD4+CD28null T Lymphocytes Frequency in Women With Hyperinsulinemia Having Polycystic Ovary Syndrome: A Randomized Clinical Trial. <i>Reproductive Sciences</i> , 2013, 20, 1508-1517.	2.5	21
90	Pathogenesis of Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2013, 61, 1-11.	2.8	209

#	ARTICLE	IF	CITATIONS
91	Effects of bariatric surgery on cardiac remodeling: Clinical and pathophysiologic implications. <i>International Journal of Cardiology</i> , 2013, 168, 4277-4279.	1.7	26
92	Identification of unique adaptive immune system signature in acute coronary syndromes. <i>International Journal of Cardiology</i> , 2013, 168, 564-567.	1.7	31
93	Interleukin-17 in atherosclerosis and cardiovascular disease: the good, the bad, and the unknown. <i>European Heart Journal</i> , 2013, 34, 556-559.	2.2	74
94	Adaptive Immunity, Inflammation, and Cardiovascular Complications in Type 1 and Type 2 Diabetes Mellitus. <i>Journal of Diabetes Research</i> , 2013, 2013, 1-11.	2.3	47
95	The Cardiovascular Relevance of Celiac Disease. <i>Diabetes Care</i> , 2012, 35, e20-e20.	8.6	5
96	CD4+CD28null T lymphocyte frequency, a new marker of cardiovascular risk: relationship with polycystic ovary syndrome phenotypes. <i>Fertility and Sterility</i> , 2012, 98, 1609-1615.	1.0	16
97	Intracoronary microparticles and microvascular obstruction in patients with ST elevation myocardial infarction undergoing primary percutaneous intervention. <i>European Heart Journal</i> , 2012, 33, 2928-2938.	2.2	95
98	Endothelial and Smooth Muscle Cells Dysfunction Distal to Recanalized Chronic Total Coronary Occlusions and the Relationship With the Collateral Connection Grade. <i>JACC: Cardiovascular Interventions</i> , 2012, 5, 170-178.	2.9	39
99	Type 2 Diabetes, Immunity and Cardiovascular Risk: A Complex Relationship. , 2012, , .		5
100	Reversible atrial gap junction remodeling during hypoxia/reoxygenation and ischemia: a possible arrhythmogenic substrate for atrial fibrillation. <i>General Physiology and Biophysics</i> , 2012, 31, 439-448.	0.9	15
101	CD4+CD28null T lymphocytes are expanded in young women with polycystic ovary syndrome. <i>Fertility and Sterility</i> , 2011, 95, 2651-2654.	1.0	22
102	Cardiovascular risk in obesity: Different activation of inflammation and immune system between obese and morbidly obese subjects. <i>European Journal of Internal Medicine</i> , 2011, 22, 418-423.	2.2	16
103	<i>Chlamydia pneumoniae</i> in coronary atherosclerotic plaques and coronary instability. <i>International Journal of Cardiology</i> , 2011, 147, 176-178.	1.7	5
104	Combined atherogenic effects of celiac disease and type 1 diabetes mellitus. <i>Atherosclerosis</i> , 2011, 217, 531-535.	0.8	48
105	Thromboxane Production in Morbidly Obese Subjects. <i>American Journal of Cardiology</i> , 2011, 107, 1656-1661.	1.6	42
106	Increase of plasma IL-9 and decrease of plasma IL-5, IL-7, and IFN- γ in patients with chronic heart failure. <i>Journal of Translational Medicine</i> , 2011, 9, 28.	4.4	60
107	Expansion of CD4+CD28null T-lymphocytes in diabetic patients: exploring new pathogenetic mechanisms of increased cardiovascular risk in diabetes mellitus. <i>European Heart Journal</i> , 2011, 32, 1214-1226.	2.2	103
108	Role of tissue C-reactive protein in atrial cardiomyocytes of patients undergoing catheter ablation of atrial fibrillation: pathogenetic implications. <i>Europace</i> , 2011, 13, 1133-1140.	1.7	16

#	ARTICLE	IF	CITATIONS
109	Role of the CD14 C(âˆ’260)T promoter polymorphism in determining the first clinical manifestation of coronary artery disease. <i>Journal of Cardiovascular Medicine</i> , 2010, 11, 20-25.	1.5	10
110	Cell survival: is not all about apoptosis: reply. <i>European Heart Journal</i> , 2010, 31, 503-504.	2.2	0
111	Predicting the no-reflow phenomenon following successful percutaneous coronary intervention. <i>Biomarkers in Medicine</i> , 2010, 4, 403-420.	1.4	8
112	Paradoxical Preservation of Vascular Function in Severe Obesity. <i>American Journal of Medicine</i> , 2010, 123, 727-734.	1.5	70
113	Different Apparent Prognostic Value of hsCRP in Type 2 Diabetic and Nondiabetic Patients with Acute Coronary Syndromes. <i>Clinical Chemistry</i> , 2009, 55, 365-368.	3.2	25
114	Gene expression profiles in peripheral blood mononuclear cells of chronic heart failure patients. <i>Physiological Genomics</i> , 2009, 38, 233-240.	2.3	68
115	Delayed neutrophil apoptosis in patients with unstable angina: relation to C-reactive protein and recurrence of instability. <i>European Heart Journal</i> , 2009, 30, 2220-2225.	2.2	28
116	Pioglitazone reduces monocyte activation in type 2 diabetes. <i>Acta Diabetologica</i> , 2009, 46, 75-77.	2.5	16
117	COX-1 sensitivity and thromboxane A2 production in type 1 and type 2 diabetic patients under chronic aspirin treatment. <i>European Heart Journal</i> , 2009, 30, 1279-1286.	2.2	78
118	Immunomodulator Activity of 3-Hydroxy-3-Methylglutaryl-CoA Inhibitors. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2009, 7, 279-294.	1.0	34
119	Association between C-reactive protein and angiographic restenosis after bare metal stents: an updated and comprehensive meta-analysis of 2747 patients. <i>Cardiovascular Revascularization Medicine</i> , 2008, 9, 156-165.	0.8	62
120	Acute Coronary Syndromes: To CRP or Not to CRP?. <i>Journal of the American College of Cardiology</i> , 2008, 52, 1500.	2.8	2
121	Effect of intensive vs standard statin therapy on endothelial progenitor cells and left ventricular function in patients with acute myocardial infarction: Statins for regeneration after acute myocardial infarction and PCI (STRAP) trial. <i>International Journal of Cardiology</i> , 2008, 130, 457-462.	1.7	69
122	Independent prognostic value of C-reactive protein and coronary artery disease extent in patients affected by unstable angina. <i>Atherosclerosis</i> , 2008, 196, 779-785.	0.8	45
123	The complex link between oxidised low-density lipoprotein and unstable angina. <i>Journal of Cardiovascular Medicine</i> , 2007, 8, 387-391.	1.5	8
124	1059G/C polymorphism within the exon 2 of the C-reactive protein gene: relationship to C-reactive protein levels and prognosis in unstable angina. <i>Coronary Artery Disease</i> , 2007, 18, 533-538.	0.7	12
125	Ischemia and apoptosis in an animal model of permanent infarct-related artery occlusion. <i>International Journal of Cardiology</i> , 2007, 121, 109-111.	1.7	12
126	Instability mechanisms in unstable angina according to baseline serum levels of C-reactive protein: The role of thrombosis, fibrinolysis and atherosclerotic burden. <i>International Journal of Cardiology</i> , 2007, 122, 245-247.	1.7	8

#	ARTICLE	IF	CITATIONS
127	Persistent Activation of Nuclear Factor Kappa-B Signaling Pathway in Patients With Unstable Angina and Elevated Levels of C-Reactive Protein. <i>Journal of the American College of Cardiology</i> , 2007, 49, 185-194.	2.8	91
128	Identification of Protein Disulfide Isomerase as a Cardiomyocyte Survival Factor in Ischemic Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2007, 50, 1029-1037.	2.8	96
129	Unusual CD4+CD28nullT Lymphocytes and Recurrence of Acute Coronary Events. <i>Journal of the American College of Cardiology</i> , 2007, 50, 1450-1458.	2.8	214
130	High Telomerase Activity in Neutrophils From Unstable Coronary Plaques. <i>Journal of the American College of Cardiology</i> , 2007, 50, 2369-2374.	2.8	64
131	Usefulness of Granulocyte Colony-Stimulating Factor in Patients With a Large Anterior Wall Acute Myocardial Infarction to Prevent Left Ventricular Remodeling (The Rigenera Study). <i>American Journal of Cardiology</i> , 2007, 100, 397-403.	1.6	55
132	Cyclo-oxygenase-2 (COX-2) inhibition reduces apoptosis in acute myocardial infarction. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2006, 11, 1061-1063.	4.9	22
133	Modulation of CD4 + CD28 null T Lymphocytes by Tumor Necrosis Factor- α Blockade in Patients With Unstable Angina. <i>Circulation</i> , 2006, 113, 2272-2277.	1.6	61
134	T cells and cytokines in atherogenesis. <i>Lupus</i> , 2005, 14, 732-735.	1.6	24
135	Laminar shear stress inhibits CXCR4 expression on endothelial cells: functional consequences for atherogenesis. <i>FASEB Journal</i> , 2005, 19, 1-25.	0.5	50
136	Mobilization of bone marrow-derived stem cells after myocardial infarction and left ventricular function. <i>European Heart Journal</i> , 2005, 26, 1196-1204.	2.2	235
137	Infarct-related artery occlusion, tissue markers of ischaemia, and increased apoptosis in the peri-infarct viable myocardium. <i>European Heart Journal</i> , 2005, 26, 2039-2045.	2.2	65
138	Widespread Myocardial Inflammation and Infarct-Related Artery Patency. <i>Circulation</i> , 2004, 110, 46-50.	1.6	114
139	Inflammation as a Possible Link Between Coronary and Carotid Plaque Instability. <i>Circulation</i> , 2004, 109, 3158-3163.	1.6	193
140	Inflammation in Acute Coronary Syndromes: Mechanisms and Clinical Implications. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2004, 57, 433-446.	0.6	7
141	Combined role of the Lewis antigenic system, Chlamydia pneumoniae, and C-reactive protein in unstable angina. <i>Journal of the American College of Cardiology</i> , 2003, 41, 546-550.	2.8	7
142	Atherothrombosis, inflammation, and diabetes. <i>Journal of the American College of Cardiology</i> , 2003, 41, 1071-1077.	2.8	236
143	Antibody Response to Chlamydial Heat Shock Protein 60 Is Strongly Associated With Acute Coronary Syndromes. <i>Circulation</i> , 2003, 107, 3015-3017.	1.6	65
144	C-Reactive Protein and Other Inflammatory Biomarkers as Predictors of Outcome Following Acute Coronary Syndromes. <i>Seminars in Vascular Medicine</i> , 2003, 03, 375-384.	2.1	32

#	ARTICLE	IF	CITATIONS
145	Prognostic Role of Plasma High-Sensitivity C-Reactive Protein Levels in Acute Coronary Syndromes. , 2003, , 291-303.		1
146	Risk of Myocardial Infarction and Angina in Patients With Severe Peripheral Vascular Disease. Circulation, 2002, 105, 800-803.	1.6	130
147	Widespread Coronary Inflammation in Unstable Angina. New England Journal of Medicine, 2002, 347, 5-12.	27.0	845
148	C-reactive protein and primary prevention of ischemic heart disease. Clinica Chimica Acta, 2001, 311, 45-48.	1.1	12
149	T-Cell Immunity in Acute Coronary Syndromes. Mayo Clinic Proceedings, 2001, 76, 1011-1020.	3.0	76
150	Molecular Fingerprint of Interferon- γ Signaling in Unstable Angina. Circulation, 2001, 103, 1509-1514.	1.6	96
151	Enhanced Response of Blood Monocytes to In Vitro Lipopolysaccharide-Challenge in Patients With Recurrent Unstable Angina. Circulation, 2001, 103, 2236-2241.	1.6	86
152	Inflammation as a Marker of Outcome in Myocardial Ischemia. , 2001, , 221-235.		1
153	Inflammation and Acute Coronary Syndromes. Herz, 2000, 25, 108-112.	1.1	35
154	Monoclonal T-Cell Proliferation and Plaque Instability in Acute Coronary Syndromes. Circulation, 2000, 101, 2883-2888.	1.6	497
155	Large, sustained cardiac lipid peroxidation and reduced antioxidant capacity in the coronary circulation after brief episodes of myocardial ischemia. Journal of the American College of Cardiology, 2000, 35, 633-639.	2.8	47
156	Perturbation of the T-Cell Repertoire in Patients With Unstable Angina. Circulation, 1999, 100, 2135-2139.	1.6	374
157	Increasing Levels of Interleukin (IL)-1Ra and IL-6 During the First 2 Days of Hospitalization in Unstable Angina Are Associated With Increased Risk of In-Hospital Coronary Events. Circulation, 1999, 99, 2079-2084.	1.6	456
158	Elevated Levels of C-Reactive Protein at Discharge in Patients With Unstable Angina Predict Recurrent Instability. Circulation, 1999, 99, 855-860.	1.6	520
159	Role of inflammation in the pathogenesis of unstable coronary artery diseases. Scandinavian Journal of Clinical and Laboratory Investigation, 1999, 59, 12-22.	1.2	22
160	Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty. Journal of the American College of Cardiology, 1999, 34, 1512-1521.	2.8	326
161	Enhanced inflammatory response in patients with preinfarction unstable angina. Journal of the American College of Cardiology, 1999, 34, 1696-1703.	2.8	144
162	Role of inflammation in the pathogenesis of unstable coronary artery diseases. Scandinavian Journal of Clinical and Laboratory Investigation, 1999, 59, 12-22.	1.2	6

#	ARTICLE	IF	CITATIONS
163	Incremental prognostic value of serum levels of troponin T and C-reactive protein on admission in patients with unstable angina pectoris. American Journal of Cardiology, 1998, 82, 715-719.	1.6	156
164	Immune system activation follows inflammation in unstable angina: pathogenetic implications. Journal of the American College of Cardiology, 1998, 32, 1295-1304.	2.8	97
165	The role of cytokines in unstable angina. Expert Opinion on Investigational Drugs, 1998, 7, 1667-1672.	4.1	12
166	Enhanced Inflammatory Response to Coronary Angioplasty in Patients With Severe Unstable Angina. Circulation, 1998, 98, 2370-2376.	1.6	292
167	Role of Inflammation in the Pathogenesis of Unstable Coronary Artery Disease. American Journal of Cardiology, 1997, 80, 10E-16E.	1.6	42
168	Differential Suppression of Thromboxane Biosynthesis by Indobufen and Aspirin in Patients With Unstable Angina. Circulation, 1997, 96, 1109-1116.	1.6	133
169	Intracellular neutrophil myeloperoxidase is reduced in unstable angina and acute myocardial infarction, but its reduction is not related to ischemia. Journal of the American College of Cardiology, 1996, 27, 611-616.	2.8	150
170	Plasminogen activation in unstable angina is associated with an acute phase response but not with activation of the hemostatic system. Journal of the American College of Cardiology, 1996, 27, 307-308.	2.8	0
171	Determinants of the acute phase response in acute myocardial infarction. European Heart Journal, 1996, 17, 1301-1302.	2.2	2
172	Episodic activation of the coagulation system in unstable angina does not elicit an acute phase reaction. American Journal of Cardiology, 1996, 77, 85-87.	1.6	33
173	Analysis of activation markers of coagulation, fibrinolysis and inflammation in unstable angina by proinflammatory transformation. Fibrinolysis, 1996, 10, 145-147.	0.5	1
174	Temporal Relation Between Ischemic Episodes and Activation of the Coagulation System in Unstable Angina. Circulation, 1996, 93, 2121-2127.	1.6	38
175	Plasma Protein Acute-Phase Response in Unstable Angina Is Not Induced by Ischemic Injury. Circulation, 1996, 94, 2373-2380.	1.6	134
176	Elevated Levels of Interleukin-6 in Unstable Angina. Circulation, 1996, 94, 874-877.	1.6	588
177	The Prognostic Value of C-Reactive Protein and Serum Amyloid A Protein in Severe Unstable Angina. New England Journal of Medicine, 1994, 331, 417-424.	27.0	2,159
178	Physiopathology of Acute Coronary Syndromes. Platelets, 1993, 4, 5-7.	2.3	0
179	Thrombin-antithrombin iii complexes during thrombolytic therapy with rt-PA in acute myocardial infarction. Fibrinolysis, 1992, 6, 71-72.	0.5	1
180	The role of the neuroimmune axis as a new frontier in atherosclerosis. European Heart Journal, 0, , .	2.2	1

#	ARTICLE	IF	CITATIONS
181	Placing the risk of myopericarditis following COVID-19 vaccination into perspective. European Heart Journal, 0, , .	2.2	0
182	Restricted T-Cell Repertoire in the Epicardial Adipose Tissue of Non-ST Segment Elevation Myocardial Infarction Patients. Frontiers in Immunology, 0, 13, .	4.8	4